NASDAQ$BTSG
Brightspring Health Services Inc · Q2 2026 earnings
Q2 2026 earnings · · Before market open
Briefing
BrightSpring Health Services Inc reported strong Q2 2026 results with 23% revenue growth driven by both segments.
BrightSpring Health Services Inc announced its Q2 2026 financial results on July 31, 2026, showing net revenue of $3.873 billion, up 23% year-over-year. Gross profit rose 31.5% to $493 million, net income from continuing operations reached $87 million, and Adjusted EBITDA increased 44.2% to $206 million. The company raised its full-year 2026 guidance and reduced leverage through debt paydown.
- Q2 revenue of $3.873 billion (+23% YoY) with Pharmacy Solutions at $3.407 billion and Provider Services at $466 million.
- Net income from continuing operations $87 million vs. $9 million prior year; Adjusted EBITDA $206 million (+44%).
- Key operational metrics improved: revenue per script +22%, home health census +54%.
- Full-year 2026 guidance raised to revenue $15.1–15.425 billion and Adjusted EBITDA $820–845 million; leverage reduced to 2.15x.
Headline financials
Revenue & EPS history
Brightspring Health Services Inc · Revenue · Quarterly
$3.87B
Revenue by segment
Brightspring Health Services Inc · $3.87B total across 2 segments · Q2 2026
- Pharmacy Solutions$3.41B—88.0%
- Provider Services$466M—12.0%
Forward guidance
Company raised full-year 2026 revenue and Adjusted EBITDA guidance, excluding Community Living and future acquisitions.
Tailwinds
- Revenue guidance increased to $15.1–15.425 billion (17.0–19.5% growth)
- Adjusted EBITDA guidance raised to $820–845 million (32.8–36.8% growth)
- Amedisys/LHC acquisition expected to contribute ~$35 million Adjusted EBITDA
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports
+4.4%
Avg return
Earnings day
+7.8%
Avg return
5 days after
+15.8%
Avg return
30 days after
75%
6 / 8 earnings
Positive
+16.6%
Q1 2025
Best reaction
-8.7%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | +9.6% | +9.9% | +28.5% | |
| Q4 2025 | +3.2% | +4.6% | +5.5% | |
| Q3 2025 | +0.5% | -2.3% | +7.8% | |
| Q2 2025 | -4.9% | -0.7% | +14.7% | |
| Q1 2025 | +16.6% | +28.7% | +33.0% | |
| Q3 2024 | +15.2% | +22.6% | +28.9% | |
| Q2 2024 | -8.7% | -8.1% | +2.6% | |
| Q1 2024 | +3.8% | +7.7% | +5.5% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro